Medical News

RSS

FDA accepts Gilead's Truvada sNDA and grants Priority Review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.

14 Feb 2012

Agilent's microarrays used in landmark study on prenatal samples

Agilent Technologies Inc. today announced its microarrays were used in a landmark research study on prenatal samples. The three-year study was designed to evaluate the accuracy, efficacy and potential advantages of using microarray analysis as compared with conventional karyotyping. Agilent SurePrint CGH microarrays and analysis software were used for the majority sample cohort of 4,400 samples.

14 Feb 2012

People with Lynch syndrome face increased risks of breast and pancreatic cancers

A new prospective study of patients with Lynch syndrome - an inherited disorder of cancer susceptibility caused by mutations in specific DNA repair genes - provides the first strong evidence that people with Lynch syndrome face significantly increased risks of breast and pancreatic cancers.

14 Feb 2012

Despite contraception compromise, Catholic bishops, Congressional Republicans vow to continue fight

At Masses across the country Sunday, Roman Catholic priests blasted the Obama administration's compromise on contraceptive insurance coverage, a sign the White House's backtrack late last week did little to defuse the controversy. The new policy requires religious employers such as universities and charities to cover contraception in employee health plans but shifts the responsibility for paying for it away from the employer and on to its health-insurance provider. Previously, the administration had required all employers apart from churches to cover contraception in their employee-insurance plans.

14 Feb 2012

CyBorD regimen shows promise against AL amyloidosis

A Mayo Clinic-led study, published in the American Society of Hematology (ASH) journal Blood found that CyBorD, a triple chemotherapy drug combination that has been successful in helping patients with the blood cancer multiple myeloma, also showed promise in improving the care for patients with the rare blood disease AL amyloidosis.

14 Feb 2012

Norwegian government introduces legal limits for 20 illegal drugs and medicines

Legal limits for twenty illegal drugs and medicines with an abuse potential have been introduced by the Norwegian government. Norway is the first country to define both impairment-based legislative limits and limits for graded sanctions for drugs other than alcohol. The Norwegian Institute of Public Health participated to provide the scientific basis for the new limits.

14 Feb 2012

Compound makes imipenem 16 times more effective against antibiotic-resistant K. pneumoniae

North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant "superbugs."

14 Feb 2012

Researchers pinpoint source of Loeys-Dietz syndrome

A USC research team has pinpointed the source of a genetic disorder that causes life-threatening birth defects, which may allow doctors to quickly diagnose and better treat the disease.

14 Feb 2012

Two novel devices can predict women at risk of premature birth

Scientists and doctors from the University of Sheffield are developing two novel devices that could lead to the improved prediction of premature births.

14 Feb 2012

Healthy older adults report less negative thinking, higher levels of life satisfaction

Study results recently published in the Journal of Aging Research found that healthy older adults reported less negative thinking compared to other age groups, leading to greater life satisfaction in seniors.

14 Feb 2012

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.

14 Feb 2012

New software key for personalized cancer medicine

High-throughput DNA sequencing technologies are leading to a revolution in how clinicians diagnose and treat cancer. The molecular profiles of individual tumors are beginning to be used in the design of chemotherapeutic programs optimized for the treatment of individual patients.

14 Feb 2012

Scientists identify more than 100 new cases of alkaptonuria

Scientists at the University of Liverpool, working with international partners, have shown a rare genetic disease, that causes crippling osteoarthritis in the spine and major joints, is far more prevalent worldwide than previously thought.

14 Feb 2012

Crop failures, returning migrants, weather patterns threatening to worsen malnutrition in Africa's Sahel, Horn regions

"Sahel states are bracing for a long, potentially deadly hungry season, many weakened by the return of people from Libya who are unemployed, armed and creating fresh strife in already-vulnerable countries," Agence France-Presse reports.

14 Feb 2012

Pacific Biosciences releases major upgrade to PacBio RS system

Pacific Biosciences of California, Inc., provider of Single Molecule Real Time sequencing products, today announced it has released a major upgrade to its PacBio RS system, referred to as "C2", including new chemistry, enhanced SMRT Cells and upgraded software, which together provide customers with significant performance increases for DNA sequencing.

13 Feb 2012

Obama's budget demonstrates his strong commitment to end HIV

"The budget President Obama outlined today yet again demonstrates his strong commitment to ending HIV by increasing funding for prevention and lifesaving care and treatment for those who cannot afford it in the United States," commented Carl Schmid, Deputy Executive Director of The AIDS Institute.

13 Feb 2012